Osteoporosis International

, Volume 19, Issue 4, pp 479–491 | Cite as

Salmon calcitonin: a review of current and future therapeutic indications

  • C. H. ChesnutIII
  • M. Azria
  • S. Silverman
  • M. Engelhardt
  • M. Olson
  • L. Mindeholm
Review

Abstract

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.

Notes

Acknowledgements

We would like to thank Peter V. Koerfgen (Novartis Pharma AG, Basle) for his valuable support in the development of this review.

Conflicts of interest

None.

References

  1. 1.
    Copp DH, Cameron EC (1961) Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science 134:2038PubMedGoogle Scholar
  2. 2.
    Azria M, Copp D, Zanelli J (1995) 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57:405–408PubMedGoogle Scholar
  3. 3.
    Woodrow JP, Noseworthy CS, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS (2003) Calcitonin/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]. J Bone Miner Res 18(Suppl 2):S37Google Scholar
  4. 4.
    Hoff A, Thomas M, Cote G (1998) Generation of a calcitonin knockout mouse model [abstract]. Bone 23:1062Google Scholar
  5. 5.
    Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF (2002) Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110:1849–1857PubMedGoogle Scholar
  6. 6.
    Hirsch PF, Baruch H (2003) Is calcitonin an important physiological substance? Endocrine 21:201–208PubMedGoogle Scholar
  7. 7.
    Thamsborg G (1999) Effect of nasal salmon calcitonin on calcium and bone metabolism. Dan Med Bull 46:118–126PubMedGoogle Scholar
  8. 8.
    Buclin T, Randin J, Jacquet A, Azria M, Attinger M, Gomez F, Burckhardt P (1987) The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 41:252–258PubMedGoogle Scholar
  9. 9.
    Wisneski L (1990) Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46(Suppl):S26–S30PubMedGoogle Scholar
  10. 10.
    Zaidi M, Inzerillo A, Troen B et al (2002) Molecular and clinical pharmacology of calcitonin. In: Bilezikian J, Raisz L, Rodan G (eds) Principles of bone biology. Academic press, San Diego, pp 1423–1440Google Scholar
  11. 11.
    Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E, Sampson D (2004) Medical management of hypercalcemia. Calcif Tissue Int 74:1–11PubMedGoogle Scholar
  12. 12.
    Hoskin D, Gilson D (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Quart J Med 211:359–368Google Scholar
  13. 13.
    Nicholson G, Moseley J, Sexton P, Mendelsohn F, Martin T (1986) Abundant calcitonin receptors in isolate rat osteoclasts, biochemical, and autoradiographic characterization. J Clin Invest 78:355–360PubMedGoogle Scholar
  14. 14.
    Holtrop N, Raisz L, Simmons H (1974) The effects of parathyroid hormone, colchicines and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol 60:346–355PubMedGoogle Scholar
  15. 15.
    Yumita S, Nicholson G, Rowe D, Kent G, Martin T (1991) Biphasic effect of calcitonin on tartrate-resistant acid phosphatase activity in isolated rat osteoclasts. J Bone Miner Res 6:591–597PubMedGoogle Scholar
  16. 16.
    Zaidi M, Inzerillo A, Moonga B, Bevis P, Huang C (2002) Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30:655–663PubMedGoogle Scholar
  17. 17.
    Chambers T, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endo Metab 57:819–824Google Scholar
  18. 18.
    Chambers T, Magnus C (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27–39PubMedGoogle Scholar
  19. 19.
    Vaananen K (2005) Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:959–971PubMedGoogle Scholar
  20. 20.
    Selander KS, Harkonen PL, Valve E, Monkkonen J, Hannuniemi R, Vaananen HK (1996) Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol 122:119–129PubMedGoogle Scholar
  21. 21.
    Plotkin L, Weinstein R, Parfitt A, Robertson P, Manolagas S, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363–1374PubMedCrossRefGoogle Scholar
  22. 22.
    Farley JR, Tarbaux NM, Hall SL, Linkhart TA, Baylink DJ (1988) The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology 123:159–167PubMedGoogle Scholar
  23. 23.
    Wallach S, Farley JR, Baylink DJ, Brenner-Gati L (1993) Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 52:335–339PubMedGoogle Scholar
  24. 24.
    Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, Nakamuta H, Koida M (2000) Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biol Pharm Bull 23:946–951PubMedGoogle Scholar
  25. 25.
    Voss A, Liese S, Priemel M, Catala-Lehnen P, Schilling AF, Mueldner C, Haberland M, Rueger JM, Emeson RB, Gagel RF, Schinke T, Amling M (2005) Uncovering the physiologic function of calcitonin using genetically modified mouse models [abstract]. J Bone Min Res (Suppl.):1162Google Scholar
  26. 26.
    Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167–171PubMedGoogle Scholar
  27. 27.
    Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2338PubMedGoogle Scholar
  28. 28.
    Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 109:267–276PubMedGoogle Scholar
  29. 29.
    Kittur S, Hoppener J, Anatonarakis S, Daniels J, Meyers D, Maestry N, Jaansen M, Korneluk R, Nelkin B, Kazaziam H (1985) Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II. Proc Natl Acad Sci 83:5064–5067Google Scholar
  30. 30.
    Nakamura M, Morimoto S, Zhang Z, Utusnomiya H, Inagami T, Ogihara T, Kakudo K (2001) Calcitonin receptor gene polymorphism in Japanese women; correlation with body mass and bone density. Calcif Tissue Int 68:211–215PubMedGoogle Scholar
  31. 31.
    Masi L, Cimaz R, Simonini G, Bindi G, Stagi S, Gozzini A, Malentacchi C, Brandi ML, Falcini F (2002) Association of low bone mass with vitamin D receptor gene and calcitonin receptor gene polymorphisms in juvenile idiopathic arthritis. J Rheumatol 29:2225–2231PubMedGoogle Scholar
  32. 32.
    Taboulet J, Frenkian M, Frendo JL, Feingold N, Jullienne A, de Vernejoul MC (1998) Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. Hum Mol Genet 7:2129–2133PubMedGoogle Scholar
  33. 33.
    Emisphere Technologies, Inc. is located in Tarrytown, NY and can be found at http://www.emisphere.com
  34. 34.
    Rico H, Hernandez ER, Revilla M, Gomez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131–138PubMedGoogle Scholar
  35. 35.
    Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8PubMedGoogle Scholar
  36. 36.
    Meschia M, Brincat M, Barbacini P, Maini MC, Marri R, Crosignani PG (1992) Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 47:53–57PubMedGoogle Scholar
  37. 37.
    Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis GP, Mazzuoli G, Miravet L et al (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 305:1124–1128PubMedGoogle Scholar
  38. 38.
    Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L (2005) Effects of Salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results From the QUEST study. J Bone Miner Res 20:1548–1561PubMedGoogle Scholar
  39. 39.
    Zikan V, Stepan J (2002) Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316:63–69PubMedGoogle Scholar
  40. 40.
    Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ (2004) Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 75:477–481PubMedGoogle Scholar
  41. 41.
    Overgaard K, Hansen MA, Nielson VA, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 89:1–6PubMedGoogle Scholar
  42. 42.
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274PubMedGoogle Scholar
  43. 43.
    Chesnut CH 3rd (2005) Personal communicationGoogle Scholar
  44. 44.
    Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435–442Google Scholar
  45. 45.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556–561PubMedCrossRefGoogle Scholar
  46. 46.
    Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 299:477–479PubMedGoogle Scholar
  47. 47.
    Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P (1994) Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69–73PubMedCrossRefGoogle Scholar
  48. 48.
    Silverman SL (2005) Quality-of-life issues in osteoporosis. Curr Rheumatol Rep 7:39–45PubMedGoogle Scholar
  49. 49.
    Chesnut CH, Richardson P, Mindeholm L (2002) Salmon calcitonin nasal spray (SCNS): effect on hip fractures in postmenopausal women [abstract]. Osteoporos Int 13(Suppl 1):128Google Scholar
  50. 50.
    Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532PubMedGoogle Scholar
  51. 51.
    Chesnut C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer R, Delmas P (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249Google Scholar
  52. 52.
    Chesnut CH III, Rosen CJ (2001) Perspective: Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163–2172PubMedGoogle Scholar
  53. 53.
    Cefalu C (2004) Is bone mineral density predictive of fracture risk reduction ? Curr Med Res Opin 20:341–349PubMedGoogle Scholar
  54. 54.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedGoogle Scholar
  55. 55.
    Olson M, Mindeholm L, Eriksen EF, Majumdar S, Azria M, Chesnut C (2006) Trabecular number as risk factor in osteoporosis and the role of nasal spray calcitonin (NS-CT) in its modification [abstract]. Osteoporos Int 17(Suppl 1):S12–S13Google Scholar
  56. 56.
    Jiang Y, Zhao J, Geusens P, Liao EY, Adriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK (2005) Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 20:125–130PubMedGoogle Scholar
  57. 57.
    Lufkin E, Sarkar S, Kulkarni M, Ciaccia A, Siddhanti S, Stock J, Plouffe L (2004) Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin 20:351–357PubMedGoogle Scholar
  58. 58.
    Marcus R, Wong M, Heath H, Stock J (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in clinical trials with fracture as endpoint. Endocr Rev 23:16–37PubMedGoogle Scholar
  59. 59.
    Boonen S, Body J, Boutsen Y, Devogelaer J, Goemaere S, Kaufman J, Rozenberg S, Reginster J (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254PubMedGoogle Scholar
  60. 60.
    Altkorn D, Vokes T (2001) Treatment of postmenopausal osteoporosis. JAMA 285:1415–1418PubMedGoogle Scholar
  61. 61.
    Hamdy R, Chesnut CH 3rd, Holick M, Leib E, Lewiecki M, Maricic M, Watts N (2005) Review of treatment modalities for postmenopausal osteoporosis. South Med J 98:1000–1014PubMedGoogle Scholar
  62. 62.
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736–746PubMedGoogle Scholar
  63. 63.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E (2002) A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521–527PubMedGoogle Scholar
  64. 64.
    Toth E, Csupor E, Meszaros S, Ferencz V, Nemeth L, McCloskey EV, Horvath C (2005) The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures-an open label study. Bone 36:47–51PubMedGoogle Scholar
  65. 65.
    Pun KK, Chan LW (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205–209PubMedGoogle Scholar
  66. 66.
    Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG (1997) Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 275:112–114PubMedGoogle Scholar
  67. 67.
    Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983PubMedGoogle Scholar
  68. 68.
    Bell NH, Avery S, Johnston CC (1970) Effects of calcitonin in Paget’s disease and polyostotic fibrous dysplasia. J Clin Endocrinol 31:283–290Google Scholar
  69. 69.
    Goldfield EB, Braiker BM, Prendergast JJ, Kolb FO (1972) Synthetic salmon calcitonin: treatment of Paget’s disease and osteogenesis imperfecta. JAMA 221:1127–1129PubMedGoogle Scholar
  70. 70.
    Kanis JA, Horn DB, Scott RDM, Strong JA (1974) Treatment of Paget’s disease of bone with synthetic salmon calcitonin. BMJ 3:727–731PubMedGoogle Scholar
  71. 71.
    Gennari C, Agnusdei D (1988) Calcitonin in bone pain management. Curr Ther Res 44:712–722Google Scholar
  72. 72.
    Rico H, Hernandez ER, Younes M, Hernandez D, Espinos D (1988) Biochemical assessment of actue and chronic treatment of Paget’s bone disease with calcitonin and calcium with and without bisphosphonate. Bone 9:63–66PubMedGoogle Scholar
  73. 73.
    Woodhouse NJY, Chalmers AH, Wells IP, Dewbury KC, Mohamedally SM (1977) Paget’s disease. Radiological changes occuring in untreated patients and those on therapy with salmon calcitonin during two years’ observation. Br J Radiol 50:699–705PubMedGoogle Scholar
  74. 74.
    Delling GR, Schultz A, Siegler R (1977) Changes of bone remodelling surfaces and bone structure in Paget’s disease following long-term treatment with calcitonin. Calcif Tissue Res 22:359–361PubMedGoogle Scholar
  75. 75.
    Fornasier VL, Stapleton K, Williams CC (1978) Histologic changes in Paget’s disease treated with calcitonin. Human Path 9:455–461Google Scholar
  76. 76.
    Evans GA, Slee GC (1977) Calcitonin for multiple fractures in Paget’s disease. Br Med J 1:357PubMedGoogle Scholar
  77. 77.
    Siris E (1999) Goals of treatment for Paget’s disease of bone. J Bone Miner Res 14(Suppl 2):49–52PubMedGoogle Scholar
  78. 78.
    Sexton PM (1992) Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol 5:251–273Google Scholar
  79. 79.
    Fischer JA, Tobler PH, Kaufmann M, Born W, Henke H, Cooper PE, Sagar SM, Martin JB (1981) Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci 78:7801–7805PubMedGoogle Scholar
  80. 80.
    Laurian L, Oberman Z, Graff E, Gilard S, Hoerer E, Simantov R (1986) Calcitonin-induced increase in ACTH, β-endorphin and cortisol secretion. Hormone Metab Res 18:268–271Google Scholar
  81. 81.
    Colado M, Ormazabal M, Goicoechea C, Lopez F, Alfaro M, Martin M (1994) Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 252:291–297PubMedGoogle Scholar
  82. 82.
    Clementi G, Prato A, Conforto G, Scapagnini U (1984) Role of serotonin in the analgesic activity of calcitonin. Eur J Pharmacol 98:449–451PubMedGoogle Scholar
  83. 83.
    Silverman SL, Azria M (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858–867PubMedGoogle Scholar
  84. 84.
    Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study. Calcif Tissue Int 49:369–372PubMedGoogle Scholar
  85. 85.
    Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, Gonelli S (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298–308Google Scholar
  86. 86.
    Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571–591PubMedGoogle Scholar
  87. 87.
    Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ (2001) Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage 21:511–526PubMedGoogle Scholar
  88. 88.
    Grunstein HS, Clifton-Bligh P, Posen S (1981) Paget’s disease of bone: experiences with 100 patients treated with salmon calcitonin. Med J Aus 2:278–280Google Scholar
  89. 89.
    Kuhlencordt F, Ringe JD, Kruse HP (1981) Behandlung der Osteodystrophia deformans Paget mit Lachs-Calcitonin. Dtsch Med Wochenschr 106:1620–1623PubMedGoogle Scholar
  90. 90.
    Peichl P, Marteau R, Griesmacher A, Kumpan W, Schedl R, Prosquil E, Fasol P, Broll H (2005) Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. J Bone Miner Metab 23:243–252PubMedGoogle Scholar
  91. 91.
    Huusko TM, Karppi P, Kautiainen H, Suominen H, Avikainen V, Sulkava R (2002) Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture. Calcif Tissue Int 71:478–484PubMedGoogle Scholar
  92. 92.
    Combe B, Cohen C, Aubin F (1997) Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 61:10–15PubMedGoogle Scholar
  93. 93.
    Maksymowych WP (1998) Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 44:2160–2166PubMedGoogle Scholar
  94. 94.
    Blau LA, Hoehns JD (2003) Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 37:564–570PubMedGoogle Scholar
  95. 95.
    Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporosis Int 16:1281–1290Google Scholar
  96. 96.
    Arinoviche R, Arriagada M, Jacobelli S, Massardo L, Rivero S, Aris H, Valenzuela M, Rojas C, Carvallo A, Gatica H et al (1987) [Calcitonin in acute pain due to vertebral fracture in osteoporosis. Cooperative study] Rev Med Chil 115(11):1039–1043PubMedGoogle Scholar
  97. 97.
    Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15:284–289PubMedGoogle Scholar
  98. 98.
    Plosker GL, McTavish D (1991) Intranasal salcatonin (salmon calcitonin): a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8:378–400Google Scholar
  99. 99.
    Clissold S, Fitton A, Chrisp P (1991) Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1:405–423PubMedGoogle Scholar
  100. 100.
    Foti R, Martorana U, Broggini M (1995) Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 56:429–435Google Scholar
  101. 101.
    Buclin T, Cosma Rochat M, Burckhardt P, Azria M, Attinger M (2002) Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17:1478–1485PubMedGoogle Scholar
  102. 102.
    Tanko LB, Bagger YZ, Alesandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C (2004) Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538PubMedGoogle Scholar
  103. 103.
    Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37:425–430PubMedGoogle Scholar
  104. 104.
    Manicourt DH, Devogelaer JP, Azria M, Silverman S (2005) Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact 5:285–293PubMedGoogle Scholar
  105. 105.
    Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, Pietryla D, Thonar EJ (1999) Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 42:1159–1167PubMedGoogle Scholar
  106. 106.
    Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Qvist P, Christiansen C (2006) Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA ? Osteoarth Cartil 14:617–624Google Scholar
  107. 107.
    Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, Bauer D, Genant H, Haskell W, Marcus R, Ott S, Torner J, Quandt S, Reiss T, Ensrud K (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1533–1541Google Scholar
  108. 108.
    Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelson T, Genant H, Christiansen C, Delmas P, Zanchetta J, Stakkestad J, Gluer C, Krueger K, Cohen F, Eckert S, Alvioloi L, Lips P, Cummings S (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637–645PubMedGoogle Scholar
  109. 109.
    Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140–1143PubMedGoogle Scholar
  110. 110.
    Harris S, Watts N, Genant H, McKeever C, Hantgartner T, Keller, M, Chesnut C, Brown J, Eriksen E, Hoseyni M, Axelrod D, Miller P (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedGoogle Scholar
  111. 111.
    Reginster JY, Minne H, Sorenson O, Hooper M, Roux C, Brandi M, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedGoogle Scholar
  112. 112.
    Meunier P, Roux C, Seeman E, Ortolanis, Badurski J, Spector T, Cannata J, Balogh A, Lemmel E, Pors-Nielsen S, Rizzoli R, Genant H, Reginster J (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedGoogle Scholar
  113. 113.

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • C. H. ChesnutIII
    • 1
  • M. Azria
    • 2
  • S. Silverman
    • 3
  • M. Engelhardt
    • 2
  • M. Olson
    • 2
  • L. Mindeholm
    • 2
  1. 1.Osteoporosis Research GroupUniversity of WashingtonSeattleUSA
  2. 2.Novartis Pharma AGBaselSwitzerland
  3. 3.Department of Medicine and RheumatologyCedars Sinai Medical CenterLos AngelesUSA

Personalised recommendations